The two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by periodic exacerbations. Drug therapy is an important component in the overall treatment of prostate disease. In addition, treatment often ends in defeat due to improper therapy, missed medications and, when the condition is alleviated, ignoring the disease.
Thus, 20-30% of patients are dissatisfied with the treatment, do not feel a reduction in the symptoms of urinary disorders and improve quality of life. This is most likely due to an incorrect assessment of lower urinary tract function in men with BPH and, accordingly, to the choice of inadequate treatment.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80–90%, including prostatodynia - 20–30%.
The most common is chronic abacterial prostatitis, which should be controlled and timely exacerbations with and without BPH should be prevented.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5α-reductase inhibitors (finasteride, dutasteride);
- α-blockers (doxazosin, tamsulosin);
- phytotherapy (sable palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (insect-derived products).
At the same time, in 13-30% of the effect of the use of α-blockers does not occur within 3 months of treatment - further treatment with drugs from this group is not recommended.
When prescribing finasteride, the physician should be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decreased ejaculate volume may lead to self-withdrawal of the drug from the patient.
The treatment of BPH and prostatitis is an important, not completely resolved urological problem.
Frequent exacerbations of CP in the absence of indications for prostate surgery force the doctor to use additional methods of drug treatment. Often the presence of concomitant CP worsens the course of BPH, as inflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine gives us new opportunities to treat CP and BPH and prevent exacerbations.